Planned sales, announced before they happen
0 trading plans running, 6 Form 144 notices for $1.9M
Plans running now
0
none adopted and not yet ended or expired
What ARE's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Trading plans
Plans adopted or ended
| Insider | What | Date | Shares | Runs to | Reported in |
|---|---|---|---|---|---|
| Hart Cole Co-President & Co-Regional Market Director – Seattle |
Ended 10b5-1 plan | Jun 25, 2026 | up to 20,000 | Jan 29, 2027 | 10-Q Aug 3, 2026 |
| Hallie E. Kuhn Executive Vice President – Capital Markets and Co-Lead – Life Science |
Ended 10b5-1 plan | Jun 18, 2026 | up to 2,574 | Oct 16, 2026 | 10-Q Aug 3, 2026 |
What the company wroteOn June 18, 2026 , Hallie E. Kuhn , our Executive Vice President – Capital Markets and Co-Lead – Life Science , terminated a Rule 10b5-1 trading arrangement that she had previously adopted in December 2025 for the sale from time to time of up to 2,574 shares of common stock. The trading arrangement was intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) and was scheduled to expire on October 16, 2026 . On June 25, 2026 , Hart Cole , our Co-President & Co-Regional Market Director – Seattle , terminated a Rule 10b5-1 trading arrangement that he had previously adopted in December 2025 for the sale from time to time of up to 20,000 shares of common stock. The trading arrangement was intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) and was scheduled to expire on January 29, 2027 . | |||||
| Marc E. Binda Chief Financial Officer and Treasurer |
Ended 10b5-1 plan | Jun 17, 2026 | up to 23,368 | Dec 1, 2026 | 10-Q Aug 3, 2026 |
What the company wroteOn June 17, 2026 , Marc E. Binda , our Chief Financial Officer and Treasurer , terminated a Rule 10b5-1 trading arrangement that he had previously adopted in December 2025 for the sale from time to time of up to 23,368 shares of common stock. The trading arrangement was intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) and was scheduled to expire on December 1, 2026 . | |||||
| Hallie E. Kuhn Executive Vice President – Capital Markets and Co-Lead – Life Science, |
Adopted 10b5-1 plan | Dec 15, 2025 | up to 2,574 | Oct 16, 2026 | 10-K Jan 26, 2026 |
What the company wroteOn December 15, 2025 , Hallie E. Kuhn , our Executive Vice President – Capital Markets and Co-Lead – Life Science, entered into a Rule 10b5-1 trading arrangement providing for the sale, from time to time, of up to 2,574 shares of common stock through October 16, 2026 . | |||||
| Marc E. Binda Chief Financial Officer and Treasurer |
Adopted 10b5-1 plan | Dec 15, 2025 | up to 23,368 | Dec 1, 2026 | 10-K Jan 26, 2026 |
What the company wroteOn December 15, 2025 , Marc E. Binda , our Chief Financial Officer and Treasurer , entered into a Rule 10b5-1 trading arrangement providing for the sale, from time to time, of up to 23,368 shares of common stock through December 1, 2026 . | |||||
| Hart Cole Co-President and Co-Regional Market Director – Seattle |
Adopted 10b5-1 plan | Dec 10, 2025 | up to 20,000 | Jan 29, 2027 | 10-K Jan 26, 2026 |
What the company wroteOn December 10, 2025 , Hart Cole , our Co-President and Co-Regional Market Director – Seattle , entered into a Rule 10b5-1 trading arrangement providing for the sale, from time to time, of up to 20,000 shares of common stock through January 29, 2027 . | |||||
| Daniel J. Ryan Co-President and Regional Market Director – San Diego |
Adopted 10b5-1 plan | Dec 16, 2024 | up to 30,000 | Aug 14, 2025 | 10-K Jan 27, 2025 |
What the company wroteOn December 16, 2024 , Daniel J. Ryan , our Co-President and Regional Market Director – San Diego , entered into a Rule 10b5-1 trading arrangement providing for the sale, from time to time, of up to 30,000 shares of common stock. The arrangement will be effective through August 14, 2025 . Mr. Ryan’s trading plan was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and our insider trading policy. | |||||
| Marc E. Binda Chief Financial Officer and Treasurer |
Adopted 10b5-1 plan | Dec 12, 2024 | up to 15,945 | Dec 12, 2025 | 10-K Jan 27, 2025 |
What the company wroteOn December 12, 2024 , Marc E. Binda , our Chief Financial Officer and Treasurer , entered into a Rule 10b5-1 trading arrangement providing for the sale, from time to time, of up to 15,945 shares of common stock through December 12, 2025 . Mr. Binda’s trading plan was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and our insider trading policy. | |||||
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since Apr 24, 2023.
Form 144
Notices of planned sales
| Filed | Seller | Shares | Value | Shares came from | 10b5-1 plan | Form 4 sales after |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | Fukuzaki-Carlson Kristina Officer |
16,810 | $849K | Restricted Stock Vesting | none given | 16,810 shares from Sep 11, 2026 |
| Aug 31, 2026 | Gavinet Andres Officer |
10,000 | $509K | Restricted Stock Vesting | none given | 10,000 shares from Aug 31, 2026 |
| Jun 9, 2026 | Binda Marc E Officer |
2,000 | $108K | Restricted Stock Vesting | adopted Dec 15, 2025 | 2,000 shares from Jun 9, 2026 |
| Apr 17, 2026 | Kuhn Hallie E. Officer |
536 | $26K | Restricted Stock Vesting | adopted Dec 15, 2025 | none found |
| Feb 27, 2026 | Gossett Bret E. Officer, Director |
4,702 | $252K | Restricted Stock Vesting | none given | none found |
| Dec 16, 2025 | Alsbrook Madeleine Thorp Officer |
3,486 | $161K | Restricted Stock Vesting | none given | none found |
From the Form 144 XML filed with the SEC, since Dec 16, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.